Monitor whether Nantahala converts its convertible securities and whether it files a 13D (activist) conversion, which would signal a more active stance. The passive certification limits near-term pressure.
GRCE drugs
GRCE drug pipeline →Price Chart
How similar events traded
Executive Summary
Nantahala Capital Management filed an amended Schedule 13G disclosing a 7.45% passive stake in Grace Therapeutics as of September 30, 2026, representing 1,654,393 shares (including 1,178,203 shares acquirable within 60 days via convertible securities). The filing updates a prior 13G/A from August 2026; the stake increased from 0% to 7.45% since the prior filing, indicating a new position was established or significantly built up.
Key Financial Metrics
Key Facts
- Nantahala Capital Management reported beneficial ownership of 1,654,393 shares of Grace Therapeutics common stock as of September 30, 2026.
- The stake represents 7.45% of shares outstanding.
- Includes 1,178,203 shares acquirable within 60 days through exercise of convertible securities.
- Filer certifies passive intent under Rule 13d-1(b), not seeking control.
- Prior 13G/A from August 2026 did not disclose any shares (0% ownership), indicating this is a new or significantly increased position.
Financial Impact
Nantahala's stake of 1,654,393 shares is valued at approximately $2.9M based on the $39M market cap and 7.45% ownership.
Risk Factors
- Convertible securities overhang could lead to dilution if exercised.
- Passive filer could later convert to activist 13D filing.
- Company has a small market cap ($39M), making large passive stakes more influential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001104659-26-127216 |
| Document: 0001104659-26-127216-index.html | 0001104659-26-127216 |
| Document: 0001104659-26-127216.txt | 0001104659-26-127216 |
Track record
15 reports on GRCE
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +10.64% at T+5 after the Apr 23, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.75 Now $1.75 0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $1.82 Now $1.75 −3.85% settles Nov 17
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $1.81 to $1.81 Now $1.75 −3.31% · 0.00% +0.36% vs SPY
- Sep 10, 20269w ago Insider Cluster Bullish 6/10 Entry $2.26 to $2.22 Now $1.75 −22.57% ▼ −1.77% −2.62% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
- Aug 13, 202613w ago Press Release Mixed 5/10 Entry $2.07 to $2.16 Now $1.75 −15.46% ▲ +4.35% +4.55% vs SPY
- Aug 4, 202614w ago Press Release Neutral 5/10 Entry $2.14 to $2.12 Now $1.75 −18.22% ▼ −0.93% −0.77% vs SPY
- Jul 28, 202615w ago 8-K Neutral 5/10 Entry $2.25 to $2.08 Now $1.75 −22.22% ▼ −7.56% −6.02% vs SPY
- Jun 18, 202621w ago 8-K Mixed 5/10 Entry $2.38 to $2.26 Now $1.75 −26.47% ▼ −5.04% −4.73% vs SPY
- Jun 18, 202621w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers